Bernard Christophe Barlaam,Andrew John Eatherton,Thomas Anthony Hunt,Kurt Gordon Pike
申请号：
US15267398
公开号：
US20170081325A1
申请日:
2016.09.16
申请国别(地区):
US
年份:
2017
代理人:
摘要：
The specification generally relates to compounds of Formula (I):and pharmaceutically acceptable salts thereof, where R1, R2, R3, R4 and R5 have any of the meanings defined herein. The specification also relates to the use of compounds of Formula (I) and salts thereof to treat or prevent ATM mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising substituted imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof； kits comprising such compounds and salts； methods of manufacture of such compounds and salts； and intermediates useful in such manufacture.
